LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company,
announced updated results from the Phase III clinical trial of Puma’s
investigational drug PB272 (neratinib) for the extended adjuvant
treatment of HER2-positive early stage breast cancer (ExteNET trial).
The ExteNET trial is a double-blind, placebo-controlled, Phase III trial
of neratinib versus placebo after adjuvant treatment with trastuzumab
(Herceptin) in women with earlymore...